Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an internati...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 13; p. 1087260
Main Authors Rong, Li, Zou, Junyan, Ran, Wei, Qi, Xiaohong, Chen, Yaokai, Cui, Hongjuan, Guo, Jinjun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 16.01.2023
Subjects
Diet
Endocrinology
exercise
Humans
medical treatment
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic Fatty Liver Disease - therapy
non-alcoholic steatohepatitis
nonalcoholic fatty liver disease
Obesity - metabolism
exercise
medical treatment
nonalcoholic fatty liver disease
diet
non-alcoholic steatohepatitis
Online AccessGet full text

Cover

More Information
Summary:Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an international consensus renamed NAFLD in 2020 as metabolic (dysfunction) associated with fatty liver disease (MAFLD). The changes in diet and lifestyle are recognized the non-drug treatment strategies; however, due to the complex pathogenesis of NAFLD, the current drug therapies are mainly focused on its pathogenic factors, key links of pathogenesis, and related metabolic disorders as targets. There is still a lack of specific drugs. In clinical studies, the common NAFLD treatments include the regulation of glucose and lipid metabolism to protect the liver and anti-inflammation. The NAFLD treatments based on the enterohepatic axis, targeting gut microbiota, are gradually emerging, and various new metabolism-regulating drugs are also under clinical development. Therefore, this review article has comprehensively discussed the research advancements in NAFLD treatment in recent years.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Gut Endocrinology, a section of the journal Frontiers in Endocrinology
Edited by: Andrea Dalbeni, Verona University Hospital, Italy
These authors have contributed equally to this work and share first authorship
Reviewed by: Hua-Tian Gan, Sichuan University, China; Zou Min, Chongqing General Hospital, China
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2022.1087260